



Management of keloid scars: noninvasive and invasive treatments

Sang Wha Kim

Department of Plastic and Reconstructive Surgery, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea

Scars vary from mature linear scars to abnormal excessive scars such as hypertrophic scars and keloid scars. Keloid scars are fibro-proliferative disease entities that reflect an abnormal process of wound healing. They can cause pain, itching, stiffness, and psychological distress, all of which can affect quality of life. Various treatment options have been advocated as ways to prevent and treat keloid scars. These include noninvasive treatments such as use of silicone gel sheeting and compression therapy, and invasive treatments such as intralesional corticosteroid injections, surgery, and radiotherapy. Novel treatments include chemotherapy, immunotherapy, and anti-inflammatory therapies. Unfortunately, keloids continue to pose a significant challenge due to the lack of efficacious treatments. Therefore, clinicians should be familiar with various therapeutic options and apply the most suitable treatment plan for patients. In this review, we introduce the current therapeutic options for the management of keloid scars.

Correspondence: Sang Wha Kim
Department of Plastic and Reconstructive Surgery, Seoul National University Hospital, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul 03080, Korea
Tel: +82-2-2072-2375
Fax: +82-2-3675-7792
E-mail: sw1215@snu.ac.kr

Keywords Scar / Keloid / Therapeutics

Received: September 25, 2020 • Revised: February 10, 2021 • Accepted: February 11, 2021
pISSN: 2234-6163 • eISSN: 2234-6171 • <https://doi.org/10.5999/aps.2020.01914> • Arch Plast Surg 2021;48:149-157

INTRODUCTION

Scars vary from mature linear scars to abnormal excessive scars such as hypertrophic scars and keloid scars. It is estimated that about 100 million people worldwide have acquired scars from surgery or trauma, of which 15% of scars are excessive [1].

According to the classification proposed by Mancini and Peacock, excessive scarring is divided into hypertrophic or keloid scarring [2]. Both types of scars rise above the skin level. However, the extent of hypertrophic scars is most commonly limited to the area of the original wound, and they sometimes spontaneously regress; in contrast, keloid scars extend beyond the boundaries of the original wound, and continue to invade the adjacent normal skin while remaining elevated [1-8]. Keloid scars are fibro-proliferative disease entities that reflect an abnormal

process of wound healing [3,9,10]. Their cause is unknown, but both genetic and environmental factors are involved [9,11].

The prevalence of keloid scars ranges from 0.09% in the United Kingdom to 16% in the Congo, with equal frequencies in both sexes [5,8,12]. Although keloid scars can occur at all ages, their incidence is high in the second and third decades of life, and injuries in young adults seem to produce more severe keloids than those in elderly people [2,3,5,9,12]. Individuals with pigmented skin are more likely to develop keloids [6], and Hispanics, African-Americans, and Asians all have an elevated risk of forming keloid scars, with a prevalence of keloid scars of 10% in the African-American population [2,3,7,9,11]. Other known risk factors are type A blood, hyper-immunoglobulin E syndrome with a high risk of allergy, and hormonal peaks such as puberty and pregnancy [11,13,14]. Keloids most frequently oc-

cur in body areas that are under tension, such as the lower abdomen and the deltoid, sternal, and suprapubic regions [6,7]. Other common locations are the shoulders, earlobes, and all areas that lack hair follicles and glands [3].

Keloid scars are not only a type of physical and aesthetic impairment, but also have psychological and social sequelae, which can further impair patients' quality of life [11,15]. They can cause significant pain, persistent itching, stiffness, and scar contracture [1,5,12,15]. In addition, they can have psychological effects, including reduced self-esteem, disruption of daily life, anxiety, and depression [1,5,12,15,16].

Various treatment options have been proposed as ways to prevent and treat keloid scars. Although differences might exist in the pathogenesis of keloid scars across ethnicities, the international advisory panel, Chinese expert consensus, and Japan scar workshop consensus have presented similar treatment options [1,17-21]. These include noninvasive treatments such as silicone gel sheeting, physiotherapy, and compression therapy, as well as invasive treatments such as intralesional corticosteroid injections, radiotherapy, cryotherapy, and surgery (Table 1) [1,17].

Despite the introduction of numerous available treatment options, keloid scars remain a therapeutic challenge. Therefore, clinicians should be familiar with the therapeutic options and to be able to provide the most suitable treatment. Here, we introduce the currently available therapeutic options and strategies, both noninvasive and invasive, for the management of keloid scars, as well as novel therapies under investigation.

NONINVASIVE TREATMENTS

Pressure garment therapy

In the past 45 years, pressure therapy was not only an option for treating keloid scars, but also the standard first-line treatment for burn scars [3,22-25]. However neither its underlying mechanism of action nor evidence of its effectiveness has been investigated [3,7,26].

Pressure therapy can be initiated after wound closure and when the patient can tolerate the pressure [18]. It requires spe-

cially-fitted garments that should be worn at least 23 hours per day. The recommended pressure is 24–30 mmHg, and the length of treatment should be 6–24 months [3,7,11,23].

Pressure garment therapy alleviates itching and pain, but its disadvantages are the cost and poor patient compliance due to the significant discomfort caused by the garments [23,27]. Furthermore, a meta-analysis reported that the potential morbidity and costs of pressure therapy appear to outweigh its benefits [11,28]. Children with keloids may be treated with pressure therapy, since the side effects are minimal compared to other invasive therapies [7].

Silicone gel sheeting

Silicone materials have been recommended as the “gold standard” treatment of keloid scars [1,29]. Their effects are thought to be related to occlusion and hydration [11,30]. Studies have reported up to 90% improvement of keloid scars following the use of silicone dressings [22]. However, although silicone materials decrease the incidence of keloids after surgical procedures, complete resolution has not been described [24,31]. Furthermore, the use of silicone materials lacks a scientific underpinning and well-designed studies [11].

Silicone materials have been manufactured as sheets and gels, which have shown equivalent efficacy [32]. It is recommended that patients wear silicone sheets for 12–24 hours per day for 3–6 months. Silicone gels should be applied twice daily [1,7].

No serious side effects have been reported, but folliculitis is a potential adverse effect [11]. Another disadvantage is that most of the available products are expensive [7].

Onion extract

The primary component of onion extract is quercetin, a flavonoid known for its anti-inflammatory, antibacterial, and collagen-suppressive properties [33]. Quercetin inhibits fibroblast proliferation and collagen production and thus reduces excess scar formation [7,34]. It also has an antihistamine effect, which is relevant for keloids since histamine increases collagen production by fibroblasts, and has therefore been implicated in the for-

Table 1. Overview of treatment options for keloid scars

Noninvasive treatment	Invasive treatment	Therapies under investigation
Pressure garment therapy	Intralesional injections (corticosteroid, 5-fluorouracil, bleomycin, mitomycin C)	Transforming growth factor-β
Silicone gel sheeting	Surgery	Botulinum toxin A
Onion extract	Cryotherapy	Angiotensin-converting enzyme inhibitor
	Radiation therapy	Calcium channel blockers
		Tacrolimus
		Imiquimod
		Interferon

mation of keloids [35,36]. However, the exact mechanism through which onion extract reduces scar formation remains to be clarified [3,37].

INTRALESIONAL INJECTIONS

Intralesional corticosteroid injections

Current international guidelines recommend intralesional corticosteroid injections as the first-line therapy for the prevention and treatment of keloids [18,19,38]. They can be used alone or in conjunction with other treatments [30].

Corticosteroids exert their effects by decreasing fibroblast proliferation, reducing collagen synthesis, altering extracellular matrix components such as glycosaminoglycan, and repressing inflammation [30,39]. The decreased collagen synthesis is thought to be due to fibroblast hypoactivity, reduced fibroblast density, and modification of fibroblast maturation [30,40]. Intralesional corticosteroid injections improve scar pliability, diminish scar volume and height, and lead to rapid clinical improvement of associated symptoms such as itching and pain [7,11,41].

Triamcinolone acetonide is used clinically at concentrations between 10 and 40 mg/mL, with 2 to 3 injections per month administered for 6 months or even longer, depending on the location, size, and volume of the keloid, as well as the individual patient's characteristics [6,39,42]. Although injections are painful, the response rate ranges from 50% to 100% and the recurrence rate is 9% to 50% [6,7,32,42]. The results can be improved by combining the injections with other treatments, such as surgery, 5-fluorouracil, and cryotherapy [11,13,22,38]. When injections were employed as adjuvant therapy after surgery, recurrence rates varied from 1% to 100%, but were less than 50% in most studies [30].

The side effects of intralesional injections are pain, skin atrophy, hypopigmentation, hyperpigmentation, and telangiectasia [6,42,43].

5-Fluorouracil

Since keloids display a cellular hypermetabolic state, antineoplastic agents have been considered as a reasonable form of therapy. 5-Fluorouracil has been employed as a treatment option for keloids for more than 25 years, but its use remains controversial [44].

5-Fluorouracil is a fluorinated pyrimidine analogue and a classical chemotherapeutic agent [30,45]. It functions as a cytotoxic agent, inhibiting cell proliferation in the scar tissue [7,44,45], and has been shown to inhibit fibroblast proliferation and enhance fibroblast apoptosis without causing tissue necrosis. It also inhibits transforming growth factor- β (TGF- β)-induced

expression of type I collagen [46-48].

Intralesional 5-fluorouracil has been used alone, in conjunction with corticosteroids, or as adjuvant therapy after surgery [1,7,30]. It was effective in 45%–96% of patients, and yielded better results when combined with corticosteroid treatment [46]. The recommended ratio is 9:1 (0.9 mL of 50 mg/mL 5-fluorouracil: 0.1 mL of 40 mg/mL triamcinolone) monthly, if corticosteroid injections have failed or in particularly severe cases [7].

The side effects of 5-fluorouracil include pain, burning sensation, purpura formation, temporary hyperpigmentation, skin erythema, and ulceration [3,7,13,41,48]. However, intralesional 5-fluorouracil treatment is safe, and no systemic complications such as anemia, leukopenia, or thrombocytopenia have been reported [3,49].

Bleomycin

Bleomycin is a cytotoxic anticancer agent with antibacterial and antiviral activities [49-51]. It induces apoptosis and reduces TGF- β 1-induced collagen synthesis [30,51-53].

Intralesional injections of bleomycin start at 0.1 mL (1.5 IU/mL) and can be increased to a maximum dose of 6 mL, with two to six sessions per month for keloids that are unresponsive to intralesional corticosteroid injections [3,53].

Side effects include pain, superficial ulceration and crusting at injection sites, transient hyperpigmentation, and dermal atrophy [49,54]. No systemic toxicity, such as pulmonary, renal, cutaneous, hepatic, or myelogenous toxicity, has been reported for low-dose subcutaneous injections of bleomycin [53].

Mitomycin C

Mitomycin C is a derivative of *Streptomyces caespitosus*, and has antineoplastic and anti-proliferative activities [25]. It inhibits the synthesis of DNA, RNA, and protein. It also inhibits fibroblast proliferation and prevents cell division, thereby reducing scar formation both *in vitro* and *in vivo* [53,55]. There is increasing interest in the use of mitomycin C to treat keloid scars [3].

SURGERY AND OTHER INVASIVE TREATMENTS

Surgery

Surgical excision of keloids is a popular option and is recommended as the first-line treatment if disabling scar contracture is present [3,56]. However, it should be used with caution since it often creates even larger lesions, and recurrence rates are high (45%–100%) [25,57]. Adjuvant measures, such as radiotherapy,

interferon, bleomycin, cryotherapy, or corticosteroids, should be applied to avoid recurrence [11,22,31]. For example, combining corticosteroid treatment with surgery reduced the recurrence rate to less than 50%, and the recurrence rate for surgery with adjuvant radiotherapy ranged from 0% to 8.6% [25,58,59].

As a general rule, wound closure should be performed with minimal tension and sutures, and relaxed skin tension lines, leaving everted wound borders [30,56,60]. In cases of scar contracture caused by excessive tension, Z-plasty, W-plasty, or various local flaps may be indicated [56,60].

Cryotherapy

Cryotherapy leads to cellular injury and necrosis of keloid tissue. It can be administered by contact, spray, or intralesional injection [30]. Intralesional cryotherapy concentrates the area of cold within the lesion, thereby minimally affecting the external skin; it is simple, can be applied to all types of scars [3], and is more effective than contact/spray treatment [14,61].

Cryotherapy is applied monthly in multiple sessions, and the success rate after two sessions ranged from 30% to 75% [11,45]. Cryotherapy, in combination with intralesional corticosteroid injection, has been the most popular traditional treatment for keloids [3,11,41].

The most common side effect of cryotherapy is hypopigmentation, followed by blisters, local pain, and hyperpigmentation [3,7,30,62].

Radiation therapy

Radiation therapy is most effective as an adjunct to surgery [1,3]. The combination of radiation therapy and surgery was found to be the most effective treatment in severe keloid cases [11] and reduced recurrence by 55% at 30 months of follow-up [3]. The exact mechanism of action of radiotherapy is unknown [30]. It may act by inhibiting the proliferation of fibroblasts, preventing fibroblast repopulation, or inhibiting angiogenesis [63-66].

The best results can be achieved with 15–20 Gy over five or six sessions during the early postoperative period (24–48 hours after surgery) [11,41]. To reduce recurrence and simultaneously limit complications, radiotherapy is applied using a site-dependent dose. For keloids on the anterior chest wall, scapular region, or suprapubic region, 20 Gy is given in four fractions over 4 days; for earlobe keloids it is given as 10 Gy in two fractions over 2 days, and for keloids at other sites, 15 Gy in three fractions over 3 days [8,64].

The side effects of radiotherapy include acute skin reactions, such as desquamation, epilation, pigmentation, and erythema in the early period (7–10 days), while subacute and late complications include scarring, permanent pigmentation, atrophy, depig-

mentation, telangiectasia, subcutaneous fibrosis, and necrosis several weeks later [8,17].

Radiation therapy is not recommended for pregnant patients, children (less than 12 years old), or for keloids in radiosensitive locations (such as the thyroid) [30]. Concerns have been raised regarding the risk of developing cancer. Overall, the evidence suggests that cancer development on keloid scars post-radiation therapy is rare [13,67,68].

THERAPIES UNDER INVESTIGATION

Transforming growth factor- β

The TGF- β family contains several isoforms (e.g., TGF- β 1, - β 2, and - β 3) that are strongly implicated in the scarring process [2]. For example, fetal healing with no scarring was associated with a higher ratio of TGF- β 3 to TGF- β 1 and TGF- β 2. In addition, oral wounds that healed more rapidly without scars also had a higher ratio of TGF- β 3 to TGF- β 1 [69,70]. Therefore, TGF- β 3 can be considered to have anti-fibrotic properties, whereas TGF- β 1 and TGF- β 2 contribute to scarring [30,31].

A recent double-blind, placebo-controlled study of recombinant human TGF- β 3 (Avotermin) resulted in a significant reduction of scarring. Avotermin has been shown to be safe, with little systemic effect; its side effects were erythema and edema [71].

Botulinum toxin A

The use of botulinum toxin A reduces tension on the wound edges by preventing muscle contraction during the healing process, thereby reducing scar formation [9,30,72]. In fact, tension is one of the causes of keloid scars. Botulinum toxin A is given 4 to 7 days before surgery to reduce tension [17].

Intralesional botulinum toxin injections resulted in improvement of keloids in a prospective, non-controlled study [49,73], and decreased keloid volume more effectively than intralesional corticosteroid injections [49]. However, conflicting results have been reported for the therapeutic effects of botulinum toxin [8,74]. Larger, randomized, controlled studies are needed to confirm its efficacy [11].

Angiotensin-converting enzyme inhibitor

The renin-angiotensin-system has been shown to affect collagen production and wound healing [3]. Although it is still under study, the local application of captopril cream (5%) and oral administration of enalapril improved keloids with no side effects. Therefore, these may be good treatment options for keloids [41,75,76].

Calcium channel blockers

Verapamil is a calcium channel blocker that is used as an antihypertensive agent. The mechanism of action of calcium channel blockers on keloids is assumed to involve reduced levels of intracellular calcium [77], leading to increased collagenase synthesis and ultimately, reduced scar tissue [3,78].

Application of verapamil cream to keloid scars prevents recurrence after intralesional injections, and intralesional verapamil injection after surgery also increased the cure rate [79-81]. However, other studies showed no evidence for the efficacy of verapamil [82,83]. These mixed results indicate that further study research is necessary on the topic of verapamil therapy in keloid treatment.

Tacrolimus (FK-506)

Tacrolimus is a calcineurin inhibitor and an immunosuppressive medication [8,30]. When it was applied to keloid fibroblasts *in vitro*, it reduced their proliferation, migration, and collagen production [8,84]. Clinically, tacrolimus is used as a topical medication for dermatological conditions such as atopic dermatitis. One patient using tacrolimus for treatment of atopic dermatitis reported that it also reduced keloid scarring [85]. However, further research on the efficacy of tacrolimus is needed [30].

Imiquimod

Imiquimod is an immune response modulator [41,86,87]. As a Toll-like receptor agonist, it increases the production of pro-inflammatory cytokines tumor necrosis factor- α , interferon- α , and interleukin 1, 6, 8, and 12. Furthermore, it induces the expression of apoptotic genes in keloid tissue [8,14,30,41,86,88].

Imiquimod cream at a 5% concentration has been approved for treating warts, basal cell carcinoma, and actinic keratosis [13,25]. A meta-analysis demonstrated that the estimated keloid recurrence rate in patients who received adjuvant therapy with imiquimod cream after keloid surgery was 24.7% [55]. Although many clinical studies point to the effect of imiquimod in the prevention of recurrence after keloid surgery, its efficacy is still open to question [86,89].

Its reported side effects are pain, hyperpigmentation, and local skin reactions such as irritation, erythema, erosion, and crusting [30,90].

Interferon

Interferons are cytokines with antiproliferative, antifibrotic, and antiviral effects [51,91]. They have also been shown to increase collagen breakdown [22,92]. Although they have promising effects on keloids, interferon treatment is expensive and remains controversial [8,11,13,57]. Moreover, interferon injections are

painful and may require regional anesthesia [11,92].

Adverse effects are generalized flu-like symptoms (occurring in 73.7% of subjects), and pain and inflammation at the injection site [30,93,94].

Tamoxifen

Tamoxifen is a synthetic nonsteroidal anti-estrogen used to treat breast cancer [8,30]. It also has an antifibrotic effect, with success in treating retroperitoneal fibrosis and desmoid tumors [95,96].

It has been shown to inhibit proliferation of cultured keloid fibroblasts, and to decrease collagen synthesis by these fibroblasts, by lowering TGF- β 1 production [97,98]. However, further studies are needed to determine the potential impact of this medication on keloids.

AN ALGORITHM FOR THE MANAGEMENT OF KELOID SCARS

An international, multidisciplinary group composed of 24 experts (including dermatologists, plastic surgeons, general surgeons, medical, rehabilitation and burn specialists, psychosocial and behavioral researchers, epidemiologists, and beauticians) recently developed a set of practical guidelines for the prevention and treatment of linear, hypertrophic, and keloid scars [1,22].

For keloids, the primary treatment recommended was silicone gel sheeting with compression therapy and moisturizing. If keloids continue to grow, silicone gel sheeting and pressure therapy, as well as intralesional injections of corticosteroids (5-fluorouracil, bleomycin or verapamil can also be considered) are recommended in combination. If there is no response, surgical excision (along with a skin graft or flap) may be considered,

Table 2. Practical guidelines for scar management

Treatment period	Keloid
Start	Avoid sun exposure Beginning keloid: Silicone gel sheeting + compression Moisturizing
4 Weeks–6 months	Growing keloid: In combination: Silicone gel sheeting and Intralesional injections of corticosteroids (5-fluorouracil, bleomycin, or verapamil can also be considered)
After 12 months	If there is no response: Consider surgical excision (with a skin graft or flap) combined with iridium, other localized radiotherapy, or intralesional cryotherapy

combined with iridium, other localized radiotherapy, or intralesional cryotherapy (Table 2) [1,17].

NOTES

Conflict of interest

No potential conflict of interest relevant to this article was reported.

ORCID

Sang Wha Kim <https://orcid.org/0000-0003-0430-3458>

REFERENCES

1. Monstrey S, Middelkoop E, Vranckx JJ, et al. Updated scar management practical guidelines: non-invasive and invasive measures. *J Plast Reconstr Aesthet Surg* 2014;67:1017-25.
2. Bailey JN, Waite AE, Clayton WJ, et al. Application of topical mitomycin C to the base of shave-removed keloid scars to prevent their recurrence. *Br J Dermatol* 2007;156:682-6.
3. Mari W, Alsabri SG, Tabal N, et al. Novel insights on understanding of keloid scar: article review. *J Am Coll Clin Wound Spec* 2016;7:1-7.
4. Alster TS, Tanzi EL. Hypertrophic scars and keloids: etiology and management. *Am J Clin Dermatol* 2003;4:235-43.
5. Bayat A, McGrouther DA, Ferguson MW. Skin scarring. *BMJ* 2003;326:88-92.
6. Juckett G, Hartman-Adams H. Management of keloids and hypertrophic scars. *Am Fam Physician* 2009;80:253-60.
7. Poetschke J, Gauglitz GG. Current options for the treatment of pathological scarring. *J Dtsch Dermatol Ges* 2016;14:467-77.
8. Huang C, Liu L, You Z, et al. Managing keloid scars: from radiation therapy to actual and potential drug deliveries. *Int Wound J* 2019;16:852-9.
9. Wilson AM. Eradication of keloids: surgical excision followed by a single injection of intralesional 5-fluorouracil and botulinum toxin. *Can J Plast Surg* 2013;21:87-91.
10. Huang C, Akaishi S, Hyakusoku H, et al. Are keloid and hypertrophic scar different forms of the same disorder? A fibroproliferative skin disorder hypothesis based on keloid findings. *Int Wound J* 2014;11:517-22.
11. Arno AI, Gauglitz GG, Barret JP, et al. Up-to-date approach to manage keloids and hypertrophic scars: a useful guide. *Burns* 2014;40:1255-66.
12. Ashcroft GS, Horan MA, Ferguson MW. Aging alters the inflammatory and endothelial cell adhesion molecule profiles during human cutaneous wound healing. *Lab Invest* 1998;78:47-58.
13. Gauglitz GG, Korting HC, Pavicic T, et al. Hypertrophic scarring and keloids: pathomechanisms and current and emerging treatment strategies. *Mol Med* 2011;17:113-25.
14. Love PB, Kundu RV. Keloids: an update on medical and surgical treatments. *J Drugs Dermatol* 2013;12:403-9.
15. Bell L, McAdams T, Morgan R, et al. Pruritus in burns: a descriptive study. *J Burn Care Rehabil* 1988;9:305-8.
16. Bakker A, Maertens KJ, Van Son MJ, et al. Psychological consequences of pediatric burns from a child and family perspective: a review of the empirical literature. *Clin Psychol Rev* 2013;33:361-71.
17. Meaume S, Le Pillouer-Prost A, Richert B, et al. Management of scars: updated practical guidelines and use of silicones. *Eur J Dermatol* 2014;24:435-43.
18. Gold MH, Berman B, Clementoni MT, et al. Updated international clinical recommendations on scar management: part 1: evaluating the evidence. *Dermatol Surg* 2014;40:817-24.
19. Gold MH, McGuire M, Mustoe TA, et al. Updated international clinical recommendations on scar management: part 2: algorithms for scar prevention and treatment. *Dermatol Surg* 2014;40:825-31.
20. Lv K, Xia Z; Chinese consensus panel on the prevention and treatment of scars. Chinese expert consensus on clinical prevention and treatment of scar. *Burns Trauma* 2018;6:27.
21. Ogawa R, Akita S, Akaishi S, et al. Diagnosis and treatment of keloids and hypertrophic scars-Japan Scar Workshop Consensus Document 2018. *Burns Trauma* 2019;7:39.
22. Mustoe TA, Cooter RD, Gold MH, et al. International clinical recommendations on scar management. *Plast Reconstr Surg* 2002;110:560-71.
23. Macintyre L, Baird M. Pressure garments for use in the treatment of hypertrophic scars: a review of the problems associated with their use. *Burns* 2006;32:10-5.
24. Goldenberg G, Luber AJ. Use of intralesional cryosurgery as an innovative therapy for keloid scars and a review of current treatments. *J Clin Aesthet Dermatol* 2013;6:23-6.
25. Huang C, Ogawa R. Roles of lipid metabolism in keloid development. *Lipids Health Dis* 2013;12:60.
26. Fette A. Influence of silicone on abnormal scarring. *Plast Surg Nurs* 2006;26:87-92.
27. Ripper S, Renneberg B, Landmann C, et al. Adherence to pressure garment therapy in adult burn patients. *Burns* 2009;35:657-64.
28. Anzarut A, Olson J, Singh P, et al. The effectiveness of pressure garment therapy for the prevention of abnormal scarring after burn injury: a meta-analysis. *J Plast Reconstr Aes-*

- thet Surg 2009;62:77-84.
29. Mustoe TA. Evolution of silicone therapy and mechanism of action in scar management. *Aesthetic Plast Surg* 2008;32: 82-92.
 30. Berman B, Maderal A, Raphael B. Keloids and hypertrophic scars: pathophysiology, classification, and treatment. *Dermatol Surg* 2017;43 Suppl 1:S3-18.
 31. Butler PD, Longaker MT, Yang GP. Current progress in keloid research and treatment. *J Am Coll Surg* 2008;206:731-41.
 32. de Oliveira GV, Nunes TA, Magna LA, et al. Silicone versus nonsilicone gel dressings: a controlled trial. *Dermatol Surg* 2001;27:721-6.
 33. Saulis AS, Mogford JH, Mustoe TA. Effect of Mederma on hypertrophic scarring in the rabbit ear model. *Plast Reconstr Surg* 2002;110:177-83.
 34. Wong TW, Chiu HC, Chang CH, et al. Silicone cream occlusive dressing: a novel noninvasive regimen in the treatment of keloid. *Dermatology* 1996;192:329-33.
 35. Kikuchi K, Kadono T, Takehara K. Effects of various growth factors and histamine on cultured keloid fibroblasts. *Dermatology* 1995;190:4-8.
 36. Kupietzky A, Levi-Schaffer F. The role of mast cell-derived histamine in the closure of an in vitro wound. *Inflamm Res* 1996;45:176-80.
 37. Hosnuter M, Payasli C, Isikdemir A, et al. The effects of onion extract on hypertrophic and keloid scars. *J Wound Care* 2007;16:251-4.
 38. Ho WS, Ying SY, Chan PC, et al. Use of onion extract, heparin, allantoin gel in prevention of scarring in Chinese patients having laser removal of tattoos: a prospective randomized controlled trial. *Dermatol Surg* 2006;32:891-6.
 39. Wolfram D, Tzankov A, Pulzl P, et al. Hypertrophic scars and keloids: a review of their pathophysiology, risk factors, and therapeutic management. *Dermatol Surg* 2009;35:171-81.
 40. Hochman B, Locali RF, Matsuoka PK, et al. Intralesional triamcinolone acetonide for keloid treatment: a systematic review. *Aesthetic Plast Surg* 2008;32:705-9.
 41. Atiyeh BS. Nonsurgical management of hypertrophic scars: evidence-based therapies, standard practices, and emerging methods. *Aesthetic Plast Surg* 2007;31:468-92.
 42. Robles DT, Moore E, Draznin M, et al. Keloids: pathophysiology and management. *Dermatol Online J* 2007;13:9.
 43. Sadeghinia A, Sadeghinia S. Comparison of the efficacy of intralesional triamcinolone acetonide and 5-fluorouracil tattooing for the treatment of keloids. *Dermatol Surg* 2012;38: 104-9.
 44. Khan MA, Bashir MM, Khan FA. Intralesional triamcinolone alone and in combination with 5-fluorouracil for the treatment of keloid and hypertrophic scars. *J Pak Med Assoc* 2014;64:1003-7.
 45. Gupta S, Kalra A. Efficacy and safety of intralesional 5-fluorouracil in the treatment of keloids. *Dermatology* 2002;204: 130-2.
 46. Bijlard E, Steltenpool S, Niessen FB. Intralesional 5-fluorouracil in keloid treatment: a systematic review. *Acta Derm Venereol* 2015;95:778-82.
 47. Darougeh A, Asilian A, Shariati F. Intralesional triamcinolone alone or in combination with 5-fluorouracil for the treatment of keloid and hypertrophic scars. *Clin Exp Dermatol* 2009;34:219-23.
 48. Nanda S, Reddy BS. Intralesional 5-fluorouracil as a treatment modality of keloids. *Dermatol Surg* 2004;30:54-6.
 49. Jones CD, Guiot L, Samy M, et al. The use of chemotherapeutics for the treatment of keloid scars. *Dermatol Reports* 2015;7:5880.
 50. Crooke ST, Bradner WT. Bleomycin, a review. *J Med* 1976; 7:333-428.
 51. Perdanasari AT, Lazzeri D, Su W, et al. Developments in the use of intralesional injections keloid treatment. *Arch Plast Surg* 2014;41:620-9.
 52. Espana A, Solano T, Quintanilla E. Bleomycin in the treatment of keloids and hypertrophic scars by multiple needle punctures. *Dermatol Surg* 2001;27:23-7.
 53. Saray Y, Gulec AT. Treatment of keloids and hypertrophic scars with Dermojet injections of bleomycin: a preliminary study. *Int J Dermatol* 2005;44:777-84.
 54. Payapvipapong K, Niumpradit N, Piriyanand C, et al. The treatment of keloids and hypertrophic scars with intralesional bleomycin in skin of color. *J Cosmet Dermatol* 2015; 14:83-90.
 55. Shin JY, Yun SK, Roh SG, et al. Efficacy of 2 representative topical agents to prevent keloid recurrence after surgical excision. *J Oral Maxillofac Surg* 2017;75:401.
 56. Ogawa R, Akaishi S, Huang C, et al. Clinical applications of basic research that shows reducing skin tension could prevent and treat abnormal scarring: the importance of fascial/subcutaneous tensile reduction sutures and flap surgery for keloid and hypertrophic scar reconstruction. *J Nippon Med Sch* 2011;78:68-76.
 57. Berman B, Flores F. Recurrence rates of excised keloids treated with postoperative triamcinolone acetonide injections or interferon alfa-2b injections. *J Am Acad Dermatol* 1997;37:755-7.
 58. Akita S, Akino K, Yakabe A, et al. Combined surgical exci-

- sion and radiation therapy for keloid treatment. *J Craniofac Surg* 2007;18:1164-9.
59. Sclafani AP, Gordon L, Chadha M, et al. Prevention of earlobe keloid recurrence with postoperative corticosteroid injections versus radiation therapy: a randomized, prospective study and review of the literature. *Dermatol Surg* 1996;22:569-74.
 60. Lee KK, Mehrany K, Swanson NA. Surgical revision. *Dermatol Clin* 2005;23:141-50.
 61. Mourad B, Elfar N, Elsheikh S. Spray versus intralesional cryotherapy for keloids. *J Dermatolog Treat* 2016;27:264-9.
 62. Gupta S, Kumar B. Intralesional cryosurgery using lumbar puncture and/or hypodermic needles for large, bulky, recalcitrant keloids. *Int J Dermatol* 2001;40:349-53.
 63. Hochman B, Isoldi FC, Furtado F, et al. New approach to the understanding of keloid: psychoneuroimmune-endocrine aspects. *Clin Cosmet Investig Dermatol* 2015;8:67-73.
 64. Levy DS, Salter MM, Roth RE. Postoperative irradiation in the prevention of keloids. *AJR Am J Roentgenol* 1976;127:509-10.
 65. Keeling BH, Whitsitt J, Liu A, et al. Keloid removal by shave excision with adjuvant external beam radiation therapy. *Dermatol Surg* 2015;41:989-92.
 66. van Leeuwen MC, Stokmans SC, Bulstra AE, et al. Surgical excision with adjuvant irradiation for treatment of keloid scars: a systematic review. *Plast Reconstr Surg Glob Open* 2015;3:e440.
 67. Shen J, Lian X, Sun Y, et al. Hypofractionated electron-beam radiation therapy for keloids: retrospective study of 568 cases with 834 lesions. *J Radiat Res* 2015;56:811-7.
 68. McKeown SR, Hatfield P, Prestwich RJ, et al. Radiotherapy for benign disease; assessing the risk of radiation-induced cancer following exposure to intermediate dose radiation. *Br J Radiol* 2015;88:20150405.
 69. O'Kane S, Ferguson MW. Transforming growth factor beta s and wound healing. *Int J Biochem Cell Biol* 1997;29:63-78.
 70. Schrementi ME, Ferreira AM, Zender C, et al. Site-specific production of TGF-beta in oral mucosal and cutaneous wounds. *Wound Repair Regen* 2008;16:80-6.
 71. Occlleston NL, O'Kane S, Laverty HG, et al. Discovery and development of avotermin (recombinant human transforming growth factor beta 3): a new class of prophylactic therapeutic for the improvement of scarring. *Wound Repair Regen* 2011;19 Suppl 1:s38-48.
 72. Sherris DA, Gassner HG. Botulinum toxin to minimize facial scarring. *Facial Plast Surg* 2002;18:35-9.
 73. Xiao Z, Zhang F, Cui Z. Treatment of hypertrophic scars with intralesional botulinum toxin type A injections: a preliminary report. *Aesthetic Plast Surg* 2009;33:409-12.
 74. Gauglitz GG, Bureik D, Dombrowski Y, et al. Botulinum toxin A for the treatment of keloids. *Skin Pharmacol Physiol* 2012;25:313-8.
 75. Ardekani GS, Aghaie S, Nemati MH, et al. Treatment of a postburn keloid scar with topical captopril: report of the first case. *Plast Reconstr Surg* 2009;123:112e-113e.
 76. Iannello S, Milazzo P, Bordonaro F, et al. Low-dose enalapril in the treatment of surgical cutaneous hypertrophic scar and keloid: two case reports and literature review. *MedGenMed* 2006;8:60.
 77. Grossman E, Messerli FH. Calcium antagonists. *Prog Cardiovasc Dis* 2004;47:34-57.
 78. Margaret Shanthi FX, Ernest K, Dhanraj P. Comparison of intralesional verapamil with intralesional triamcinolone in the treatment of hypertrophic scars and keloids. *Indian J Dermatol Venereol Leprol* 2008;74:343-8.
 79. Danielsen PL, Rea SM, Wood FM, et al. Verapamil is less effective than triamcinolone for prevention of keloid scar recurrence after excision in a randomized controlled trial. *Acta Derm Venereol* 2016;96:774-8.
 80. D'Andrea F, Brongo S, Ferraro G, et al. Prevention and treatment of keloids with intralesional verapamil. *Dermatology* 2002;204:60-2.
 81. Lawrence WT. Treatment of earlobe keloids with surgery plus adjuvant intralesional verapamil and pressure earrings. *Ann Plast Surg* 1996;37:167-9.
 82. El-Kamel MF, Selim MK, Alghobary MF. Keloidectomy with core fillet flap and intralesional verapamil injection for recurrent earlobe keloids. *Indian J Dermatol Venereol Leprol* 2016;82:659-65.
 83. Aggarwal A, Ravikumar BC, Vinay KN, et al. A comparative study of various modalities in the treatment of keloids. *Int J Dermatol* 2018;57:1192-200.
 84. Wu CS, Wu PH, Fang AH, et al. FK506 inhibits the enhancing effects of transforming growth factor (TGF)- β 1 on collagen expression and TGF- β /Smad signalling in keloid fibroblasts: implication for new therapeutic approach. *Br J Dermatol* 2012;167:532-41.
 85. Kim A, DiCarlo J, Cohen C, et al. Are keloids really "glioids"? High-level expression of gli-1 oncogene in keloids. *J Am Acad Dermatol* 2001;45:707-11.
 86. Viera MH, Caperton CV, Berman B. Advances in the treatment of keloids. *J Drugs Dermatol* 2011;10:468-80.
 87. Berman B, Villa A. Imiquimod 5% cream for keloid management. *Dermatol Surg* 2003;29:1050-1.
 88. Martin-Garcia RF, Busquets AC. Postsurgical use of imiqui-

- mod 5% cream in the prevention of earlobe keloid recurrences: results of an open-label, pilot study. *Dermatol Surg* 2005;31:1394-8.
89. Berman B, Harrison-Balestra C, Perez OA, et al. Treatment of keloid scars post-shave excision with imiquimod 5% cream: a prospective, double-blind, placebo-controlled pilot study. *J Drugs Dermatol* 2009;8:455-8.
90. Cacao FM, Tanaka V, Messina MC. Failure of imiquimod 5% cream to prevent recurrence of surgically excised trunk keloids. *Dermatol Surg* 2009;35:629-33.
91. Edwards L. The interferons. *Dermatol Clin* 2001;19:139-46.
92. Tredget EE, Wang R, Shen Q, et al. Transforming growth factor-beta mRNA and protein in hypertrophic scar tissues and fibroblasts: antagonism by IFN-alpha and IFN-gamma in vitro and in vivo. *J Interferon Cytokine Res* 2000;20:143-51.
93. Leventhal D, Furr M, Reiter D. Treatment of keloids and hypertrophic scars: a meta-analysis and review of the literature. *Arch Facial Plast Surg* 2006;8:362-8.
94. Lee JH, Kim SE, Lee AY. Effects of interferon-alpha2b on keloid treatment with triamcinolone acetonide intralesional injection. *Int J Dermatol* 2008;47:183-6.
95. Kinzbrunner B, Ritter S, Domingo J, et al. Remission of rapidly growing desmoid tumors after tamoxifen therapy. *Cancer* 1983;52:2201-4.
96. Clark CP, Vanderpool D, Preskitt JT. The response of retroperitoneal fibrosis to tamoxifen. *Surgery* 1991;109:502-6.
97. Chau D, Mancoll JS, Lee S, et al. Tamoxifen downregulates TGF-beta production in keloid fibroblasts. *Ann Plast Surg* 1998;40:490-3.
98. Mikulec AA, Hanasono MM, Lum J, et al. Effect of tamoxifen on transforming growth factor beta1 production by keloid and fetal fibroblasts. *Arch Facial Plast Surg* 2001;3:111-4.